NEW YORK–(BUSINESS WIRE)–Jan. 2, 2019– IVERIC bio Corporation (NASDAQ: ISEE) announced today the election of Calvin (Cal) W. Roberts, M.D., Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of January 1. Dr. Roberts brings over 25 years of experience in the pharma/biotech industry and is well-respected for his business expertise, industry experience and ophthalmic leadership.
“We are excited to welcome Dr. Roberts, a well-known physician and experienced executive in our industry, to our Board of Directors,” stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio and David R. Guyer, M.D., Executive Chairman of IVERIC bio.
Mr. Sblendorio added, “The magnitude of relevant ophthalmic expertise and industry experience that Cal brings to IVERIC bio is extremely valuable as we continue to develop and advance our pipeline of novel therapeutics and gene therapies for retinal diseases. We believe the addition of Cal to our Board is another important step as we focus on creating value for shareholders.”
“As IVERIC bio positions itself at the forefront of developing transformative treatments for orphan and age-related retinal diseases, I am excited to join the Board of IVERIC bio at this important time,” stated Dr. Roberts. “Forming partnerships between industry and physicians is extremely important to me, and I look forward to working closely with the Board and management team to build on the foundation that Ophthotechhas created.”
Calvin (Cal) W. Roberts, M.D.
Calvin W. Roberts, M.D. is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. Dr. Roberts is a Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts has served as a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals. Dr. Roberts received an A.B. from Princeton University and his M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.
About IVERIC bio Corporation
Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. For more information, please visit www.ivericbio.com.
Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about IVERIC bio’s strategy, future operations and future expectations and plans and prospects for Ophthotech, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, Ophthotech’s forward looking statements include statements about the implementation of its strategic plan. Such forward-looking statements involve substantial risks and uncertainties that could cause Ophthotech’s performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory matters, need for additional financing and negotiation and consummation of in-license and/or acquisition transactions and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that IVERIC bio files with the Securities and Exchange Commission. Any forward-looking statements represent Ophthotech’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so except as required by law.
Source: IVERIC bio Corporation
IVERIC bio Corporation
Vice President, Investor Relations and Corporate Communications
Alex Van Rees, 973-442-1555 ext. 111
SmithSolve LLC on behalf of IVERIC bio Corporation